Chokhani Pharma made a proposal for establishing a joint production facility in Belarus to manufacture medications for hepatitis. This was discussed at a meeting in the Council of the Republic by Mikhail Myasnikovich, the speaker of the upper house of Belarusian parliament; Vladimir Gusakov, the Chairman of the Presidium of the National Academy of Sciences (NAS); and Lalit Chokhani, the Director of the Indian pharmaceutical company.
Chokhani Pharma closely collaborates with Academpharm, an enterprise established at the facilities of the NAS of Belarus. According to Vladimir Gusakov, the Indian side proposed a new interesting project to create a number of advanced drugs for the treatment of hepatitis, including Sofosbuvir. Currently, almost all such drugs are imported, primarily from Egypt. Vladimir Gusakov said that Academpharm sees the benefits in collaborating with a large Indian drug manufacturer. He added that the plans include setting up the production of medicines not only in the form of tablets, but also aerosols.
During the meeting, Mikhail Myasnikovich expressed his readiness to support mutually beneficial projects. The Chairman of the Council of the Republic was also informed on the development of the pharmaceutical cluster of NAS, which includes the Institute of Bioorganic Chemistry, Academpharm, and other enterprises.